mifepristone has been researched along with goserelin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bakker, GH; De Jong, FH; Foekens, JA; Klijn, JG; Portengen, H; Setyono-Han, B | 1 |
1 review(s) available for mifepristone and goserelin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for mifepristone and goserelin
| Article | Year |
|---|---|
Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cytosol; Drug Implants; Estrenes; Female; Follicle Stimulating Hormone; Goserelin; Injections, Subcutaneous; Luteinizing Hormone; Mammary Neoplasms, Experimental; Mifepristone; Progestins; Rats; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1989 |